Study to Evaluate Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-291 Moves Through the Body in Adult Participants With Non-Hodgkin's Lymphoma

Официальное название

A Phase 1 First-In-Human Study Evaluating Safety, Pharmacokinetics, and Efficacy of ABBV 291 as Monotherapy and in Combination in Non-Hodgkin's Lymphoma

Обзор

Non-Hodgkin's lymphoma (NHL) is a cancer that arises from the transformation of normal B and T lymphocytes (white blood cells). The purpose of this study is to assess the safety, tolerability, pharmacokinetics, and preliminary efficacy of ABBV-291 in adult participants in relapsed or refractory (R/R) NHL, including but not limited to diffuse large b-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), and follicular lymphoma (FL). Adverse events will be assessed. ABBV-291 is an investigational drug being developed for the treatment of NHL. This study will include a dose escalation phase to determine the maximum administered dose (MAD)/Maximum tolerated dose (MTD) of ABBV-291 and a dose expansion/optimization phase to determine the change in disease activity in participants with R/R NHL. Approximately 165 adult participants with multiple NHL subtypes will be enrolled in the study in sites world wide In the dose escalation phase of the study participants will receive escalating Intravenously (IV) infused doses of ABBV-291, until the MAD/MTD is determined. In the dose expansion/optimization phase of the study participants receive IV infused ABBV-291, as part of the approximately 74 month study duration. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at an approved institution (hospital or clinic). The effect of the treatment will be frequently checked by medical assessments, blood tests, and side effects.

Вмешательства

• Препарат ABBV-291
  Intravenous Infusion

Первичные конечные точки

• Percentage of Participants with Adverse Events (AE)s [Срок оценки: Up to 74 Months]
• Percentage of Participants with Dose Limiting Toxicities (DLT)s [Срок оценки: Up to 74 Months]
• Percentage of Participants with Clinically Significant Laboratory Values (Chemistry, and Hematology) [Срок оценки: Up to 74 Months]
• Percentage of Participants with Clinically Significant Vital Sign Measurements [Срок оценки: Up to 74 Months]
• Percentage of Participants with Clinically Significant Electrocardiogram (ECG) Findings [Срок оценки: Up to 74 Months]
• Objective Response Rate (ORR) [Срок оценки: Up to 74 Months]

Вторичные конечные точки (7)

• Duration of Response (DOR) as Assessed by Investigator [Срок оценки: Up to 74 Months]
• Progression-Free Survival (PFS) as Assessed by Investigator [Срок оценки: Up to 74 Months]
• Time to response (TTR) [Срок оценки: Up to 74 Months]
• Area Under the Curve (AUC) of ABBV-291 [Срок оценки: Up to 12 Months]
• Maximum Observed Plasma/Serum Concentration (Cmax) of ABBV-291 [Срок оценки: Up to 12 Months]
• Time to Cmax (Tmax) of ABBV-291 [Срок оценки: Up to 12 Months]
• Half-Life (t1/2) of ABBV-291 [Срок оценки: Up to 12 Months]

Критерии участия

Критерии включения

• For dose escalation (Part 1) only: Participants must have documented diagnosis of B-cell malignancies including (but not limited to) the following, with histology based on criteria established by the World Health Organization (WHO), and measurable disease requiring treatment:

• Mantle cell lymphoma (MCL);
• Marginal zone lymphoma (MZL);
• Waldenstrom macroglobulinemia (WM);
• Diffuse large b-cell lymphoma (DLBCL) (including: germinal center B-cell type, activated B-cell type, primary cutaneous DLBCL \[leg type\], Epstein-Barr virus-positive (EBV+) DLBCL \[not otherwise specified\], DLBCL associated with chronic inflammation, human herpesvirus 8-positive \[HHV8+\] DLBCL \[not otherwise specified\], B cell lymphoma \[unclassifiable\] with features intermediate between DLBCL and classical Hodgkin lymphoma, high-grade B-cell lymphoma \[not otherwise specified\], high-grade B-cell lymphoma \[with MYC (avian myelocytomatosis viral oncogene homolog) and BCL2 and/or BCL6 rearrangements\], DLBCL arising from follicular lymphoma \[FL\] \[transformed FL\]);
• FL Grades 1 to 3B;
• For dose expansion (Part 2) only: Participants must have documented diagnosis of one of the following B-cell malignancies, with histology based on criteria established by the WHO, and measurable disease requiring treatment:

• Part 2a only: DLBCL (including: germinal center B-cell type, activated B-cell type, primary cutaneous DLBCL \[leg type\], EBV+ DLBCL \[not otherwise specified\], DLBCL associated with chronic inflammation, HHV8+ DLBCL \[not otherwise specified\], B-cell lymphoma \[unclassifiable\] with features intermediate between DLBCL and classical Hodgkin lymphoma, high-grade B-cell lymphoma \[not otherwise specified\], high-grade B-cell lymphoma \[with MYC and BCL2 and/or BCL6 rearrangements\], DLBCL arising from FL \[transformed FL\]);
• Part 2b only: FL Grades 1 to 3B;
• Part 2c only: Mantle cell lymphoma;
• For all participants (Parts 1 and 2):

• Must be considered relapsed or refractory to, or intolerant of, at least 2 or more prior lines of therapy known to provide a clinical benefit for their condition, and for whom there is no appropriate locally available therapy known to provide clinical benefit (e.g., standard chemotherapy or autologous stem cell transplantation \[ASCT\]).
• Indolent non-Hodkin's lymphoma (NHL) participants must meet relevant disease specific requirements for treatment (e.g., National Comprehensive Cancer Network \[NCCN\], Groupe d'Etude des Lymphomes Folliculaires \[GELF\]).
• History of allogeneic stem cell transplantation must be stable off of immunosuppression for at least 3 months.
• For participants enrolled in backfill cohorts or at dose levels previously cleared, subjects must provide consent to an on-treatment fresh tumor biopsy from the same tumor lesion as the baseline tumor tissue. This requirement may be waived at the discretion of the contract research organization (CRO) Medical Monitor if collecting a biopsy would place the subject at risk of harm or would require a technically complicated procedure based on tumor location as assessed by the investigator or could hinder a subject's ability to participate in the study.
• Previously treated with a CD79b-targeting therapy (e.g., CD79b monoclonal antibody) a core or excision tumor biopsy subsequent to the most recent CD79b-targeting therapy must be collected. Tumor biopsy requirements may be modified by Sponsor during the study. This requirement may be waived at the discretion of the contract research organization (CRO) Medical Monitor if collecting a biopsy would place the subject at risk of harm or would require a technically complicated procedure based on tumor location as assessed by the investigator or could hinder a subject's ability to participate in the study.

• CD79b expression status will be assessed in all participants.
• Have an eastern cooperative oncology group (ECOG) Performance Status of 0 or 1.
• Laboratory values meeting the criteria in the protocol within the screening period prior to the first dose of study drug (if multiple samples are drawn within the screening period, the sample/result immediately prior to Cycle 1 Day 1 is applicable).
• Availability of representative baseline tumor tissue (most recent archived tumor tissue or fresh biopsy collected during screening phase) suitable for immunohistochemistry (IHC) testing. This requirement may be waived at the discretion of the CRO Medical Monitor if collecting a biopsy at screening would place the participant at risk of harm or would require a technically complicated procedure based on tumor location as assessed by the investigator or could hinder a participant's ability to participate in the study.

Критерии исключения

• History of interstitial lung disease (ILD) or pneumonitis that required treatment with systemic steroids, or any evidence of active ILD or pneumonitis.
• Treatment with any of the following:

• Anticancer therapy including chemotherapy, radiotherapy, small molecule, investigational, and biologic agents within 14 days (or at least 5 half-lives, whichever is shorter), prior to the first dose of the study treatment;
• CD79b-directed agents (e.g., CD79b monoclonal antibody therapy) within 4 weeks (or at least 5 half-lives, whichever is shorter) prior to the first dose of study treatment.
• Prior treatment with an antibody drug conjugate that consists of a topoisomerase I inhibitor.

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Нет

Дизайн исследования

Распределение

Нерандомизированное

Модель

Последовательный дизайн

Маскирование

Открытое

Основная цель

Лечение

Центры проведения

США · 5 центров

• Carolina BioOncology Institute /ID# 265259 — Huntersville
• Willamette Valley Cancer Institute and Research Center /ID# 270945 — Eugene
• Texas Oncology - Central/South Texas /ID# 270946 — Austin
• START Mountain Region /ID# 267592 — West Valley City
• Virginia Cancer Specialists - Fairfax /ID# 265082 — Fairfax

Япония · 3 центра

• Aichi Cancer Center /ID# 267471 — Nagoya
• National Cancer Center Hospital East /ID# 261775 — Kashiwa-shi
• The Cancer Institute Hospital Of JFCR /ID# 267470 — Koto-ku

Австралия · 2 центра

• St Vincent's Hospital Melbourne /ID# 261664 — Fitzroy Melbourne
• Sir Charles Gairdner Hospital /ID# 268579 — Nedlands

Израиль · 2 центра

• Hadassah Medical Center-Hebrew University /ID# 261658 — Jerusalem
• Tel Aviv Sourasky Medical Center /ID# 261659 — Tel Aviv

Великобритания · 2 центра

• The Christie /ID# 267177 — Manchester
• University Hospitals Plymouth NHS Trust /ID# 267174 — Plymouth

Идентификаторы

NCT: NCT06667687 · M24-893 · 2024-512586-13-00

Первоисточники (государственные реестры)

• ClinicalTrials.gov (NIH, США)

Открыть это исследование на ClinicalTrials.gov ↗